Medtronic is set to spin off its diabetes division, MiniMed Group, targeting an $8 billion valuation to sharpen its focus on core operations, particularly following the recent FDA approval of its Hugo robotic surgery system. With a market value of $124 billion and a 48-year streak of increasing dividends, the company reported a strong revenue growth of 8.7% year-over-year, underscoring its robust financial health even in the face of recent market challenges. The spin-off is expected to redirect approximately $350 million towards enhancing innovation in its primary business segments.
“Medtronic · has a forward-looking price-to-earnings (P/E) ratio of · 16.3 · recent”
“Medtronic · has increased its dividend payout for · 48 consecutive years · record”
“Medtronic · payout ratio was recently about · 79% · sustainable dividend”
“Medtronic · employs more than · 13,600 scientists and engineers · in more than 150 countries”
“Medtronic · treats more than · 70 health conditions”
“Medtronic · is spending around · $2.7 billion · annually on research and development”
“Medtronic · is spinning off its diabetes division aiming for a valuation of · $8 billion · in early March”
“Medtronic · has a market value of · $124 billion · at the time of this writing”
“Medtronic · featured revenue up by · 8.7% · year over year”
“Medtronic · secured FDA approval for · Hugo robotic surgery system”
“MiniMed Group · will start trading after · being separated from Medtronic · which will still own about 90% of the company”
“MiniMed Group (MMED) · will start trading after being separated from · Medtronic (MDT) · 90%”